Introduction
Direct transfer of proapoptotic genes into cancer cells has been reported to induce apoptosis of malignant cells, achieving therapeutic benefit both in vitro and in vivo in established experimental tumor models. We and others recently showed that direct transfer of the human Bax gene to cancer cells induced apoptosis and suppressed tumor growth of both p53-sensitive and p53-resistant cancer models. [1] [2] [3] [4] We and others also showed that direct transfer of the full-length coding sequence of the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) into cancer cells elicited apoptosis and apoptotic bystander effects on malignant cells and suppressed tumor growth in vivo. 5, 6 As potent promoters of apoptosis, Bax and TRAIL elicit cell death through different apoptotic pathways. Bax, a member of Bcl-2 family, induces the release of cytochrome c from mitochondria, thus leading to activation of caspase-9, -3, and -7 and ultimately to programmed cell death. 7, 8 In contrast, the Bcl- 2 gene inhibits apoptosis by blocking the release of cytochrome c from mitochondria. 9, 10 The Bcl-2/Bax ratio has been reported to be the critical determinant of whether apoptosis is induced or inhibited; excess of Bax stimulates apoptosis, conversely, underexpression of Bax inhibits apoptosis. 11 TRAIL, a member of the TNF family, triggers apoptosis through interactions with death receptors on the cell surface. Both recombinant, soluble TRAIL and wild-type, membrane-bound TRAIL induce apoptosis in a wide variety of transformed cell lines via interaction with one or both of the death receptors DR4/TRAIL-R1 and DR5/TRAIL-R2, 12 ,13 which in turn initiates activation of caspase-8 through FADD, leading to apoptosis. [14] [15] [16] However, the antagonistic decoy receptors DcR1, 17, 18 DcR2, 19 and osteoprotegerin 20 are believed to protect normal cells from the cytotoxic effects of TRAIL by competing with DR4/TRAIL-R1 and DR5/TRAIL-R2 for TRAIL binding.
Although much work has shown that most types of cancer cells are sensitive to Bax and TRAIL gene therapy, [1] [2] [3] 5, 6, 21 little is known about development of resistance during such treatment. As with chemotherapy, repeated administration of proapoptotic genes to cancers might result in expansion or selection of malignant cells that are resistant to such treatment. Understanding the mechanisms of development of resistance during treatment and developing strategies to overcome these mechanisms are essential to ensuring the success of cancer therapy, particularly gene therapy for cancer. To investigate possible mechanisms of treatment-related resistance in Bax and TRAIL gene therapy and to develop strategies for overcoming this resistance, we repeatedly treated the human colon cancer cell line DLD1, a cell line initially very susceptible to both the Bax and the TRAIL genes, with adenoviral vectors that expressed either the Bax or the TRAIL gene. We then identified two DLD1 cell lines resistant to either adenovirus-mediated Bax gene therapy or TRAIL gene therapy. Furthermore, we found that different mechanisms are involved in the development of resistance during adenovirus-mediated proapoptotic gene therapy. Interestingly, DLD1 cells resistant to the TRAIL-expressing adenovirus are susceptible to Baxexpressing adenoviral vectors, and DLD1 cells resistant to the Bax-expressing adenovirus are susceptible to TRAIL-expressing adenoviral vectors. Our results suggest that alternative application of genes involved in different apoptotic pathways or different cell killing models may help to overcome development of resistance to adenovirus-mediated proapoptotic gene therapy.
Results

Selection of DLD1/Bax-R and DLD1/TRAIL-R cells
To determine whether resistance develops during adenovirus-mediated proapoptotic gene therapy, we treated the human colon cancer line DLD1 with binary adenoviral vectors that expressed either Bax (Ad/PKG-GV16 + Ad/GT-Bax) or TRAIL (Ad/PKG-GV16 + Ad/GT-TRAIL) at a total MOI of 1000 vp/cell. 5, 22 Seventy-two hours after infection, about 95% of cells in each treatment were apoptotic. In contrast, treatment with a control vector Ad/CMV-GFP at the same total dose resulted in only background levels of cell death that were similar to the level of apoptpsis seen in mock control. These results demonstrate that parental DLD1 cells were susceptible to both Bax and TRAIL gene delivered by adenoviral vectors. After treatment with the Bax-or TRAIL-expressing adenoviral vectors, the surviving DLD1 cells were allowed to grow in regular medium. When these cells reached 70-80% confluency, a second round of infection at the same MOI was performed. Seventy-two hours after the fourth round of infection of surviving cells with either the Bax-or the TRAIL-expressing adenoviral vectors, the level of cell death in each treatment was less than 5%, suggesting that these cells were resistant to the respective gene Bax or TRAIL driven by PGK promoter and delivered by adenoviral vectors. We named these two resistant cell lines DLD1/Bax-R and DLD1/TRAIL-R cells.
We then tested whether these two resistant cell lines were also resistant to the Bax or the TRAIL gene driven by hTERT promoter 2 and delivered by adenoviral vectors. Parental DLD1, DLD1/Bax-R and DLD1/TRAIL-R cells were treated with Ad/hTERT-GV16 + Ad/GT-Bax or with bicistronic adenoviral vector Ad/gTRAIL at a total MOI of 1000 vp/cell. PBS was used as a mock control and Ad/CMV-GFP as a vector control. In all three cell lines tested, FACS analysis showed that only background levels of cells death (1.1-4.0%) 48 h after treatment with either PBS or Ad/CMV-GFP. In parental Gene Therapy DLD1 cells, FACS analysis showed that the percentage of apoptotic (sub-G1) cells was 52.5% 48 h after treatment with Ad/hTERT-GV16 + Ad/GT-Bax and 62.7% 48 h after treatment with Ad/gTRAIL. In contrast, only 5.2% of DLD1/Bax-R cells were apoptotic 48 h after treatment with Ad/hTERT-GV16 + Ad/GT-Bax, and only 6.2% of DLD1/TRAIL-R cells were apoptotic 48 h after treatment with Ad/gTRAIL (Figure 1a) . These results demonstrated that the mechanisms of resistance of DLD1/Bax-R and DLD1/TRAIL-R cells do not involve the PGK promoter. Cell viability assay with XTT showed the same results (Figure 1b) as those of the FACS assay. Almost all parental DLD1 cells treated with Ad/hTERT-GV16 + Ad/GT-Bax or with Ad/gTRAIL were apoptotic 3 days after infection. In contrast, there was no significant difference in the cell death levels between DLD1/Bax-R cells treated with Ad/hTERT-GV16 + Ad/GT-Bax and the control vectors or between DLD1/TRAIL-R cells treated with Ad/gTRAIL and the control vectors.
Susceptibility of DLD1/Bax-R and DLD1/TRAIL-R cells to adenoviral infection
To determine whether resistance is caused by reduced adenoviral vector transduction, we evaluated the transduction efficiencies of adenoviral vectors in parental DLD1, DLD1/Bax-R, and DLD1/TRAIL-R cells. Cells were infected with either Ad/CMV-GFP or Ad/gTRAIL at a total MOI of 1000 vp/cell. Cells were harvested 48 h after infection and subjected to FACS analysis. Treatment with Ad/CMV-GFP resulted in levels of GFP-positive cells of 98 ± 2.0% for parental DLD1 cells (mean fluorescence intensity 45 ± 4.3), and 70 ± 4.5% for DLD1/Bax-R cells (mean fluorescence intensity 4 ± 1.2), and 99 ± 1.5% for DLD1/TRAIL-R cells (mean fluorescence intensity 42 ± 3.9). Thus the level of transgene expression of DLD1/TRAIL-R cells is similar to that of the parental DLD1 cells, in terms of both the percentage and the mean fluorescence intensity of GFP-positive cells. However, in DLD1/Bax-R cells, the level of transgene expression was dramatically reduced. Similar results were obtained when the three cell lines were treated with Ad/gTRAIL. Because Ad/gTRAIL expresses the GFP/TRAIL fusion protein from the hTERT promoter, analysis of GFP-positive cells allowed us to estimate levels of transgene expression after treatment with Ad/gTRAIL. Levels of transgene expression were similar in parental DLD1 and DLD1/TRAIL-R cells, but dramatically reduced in DLD1/Bax-R cells (Table 1 ). These observations were consistent with the results of Western blot analysis. Compared with parental DLD1 cells, DLD1/Bax-R cells expressed much less Bax protein after treatment with Ad/hTERT-GV16 + Ad/GT-Bax at a total MOI of 1000 vp/cell (Figure 2a ). Increasing the total vector dose to five times the original dose (Ad/hTERT-GV16 + Ad/GTBax at a total MOI of 5000 vp/cell) still did not induce Bax-R cells to express levels of Bax protein similar to the level expressed by parental DLD1 cells treated with an MOI of 1000 vp/cell.
To further investigate the differences in susceptibility to adenoviral infection in parental DLD1and DLD1/Bax-R cells, these two cell lines were infected with Ad/CMV-GFP at different MOIs. The percentage of GFP-positive cells and the mean fluorescence intensity were then determined by FACS analysis as described above. DLD1/Bax-R cells treated with an MOI of 10 000 vp/cell
Figure 1 Characterization of DLD1/Bax-R and DLD1/TRAIL-R cells. (a) Parental DLD1, DLD1/Bax-R and DLD1/TRAIL-R cells were infected with different adenovirus at a total MOI of 1000 vp/cells. Cells treated with PBS were used as a mock control. Percentages of apoptotic (sub-G1) cells were determined by FACS 48 h after treatment. Left, cell lines; top, treatments; number within each panel, percentages of apoptotic cells. (c) Cell viability was determined 24, 48 and 72 h after treatment. Cells treated with PBS were used as a mock control, and their viability was set as 100%. Values are means ± s.d. for quadruplicate assays. In parental DLD1 cells, levels of apoptosis after treatment with Ad/hTERT-GV16 + Ad/GT-Bax or Ad/gTRAIL differed significantly from levels after treatments with PBS or Ad/CMV-GFP (P Ͻ 0.01), whereas there were no differences in apoptosis levels among treatment groups for DLD1/Bax-R or DLD1/TRAIL-R cells. ᭛, PBS;
ᮀ, Ad/CMV-GFP; ̅, Ad/gTRAIL; ᭺, Ad/hTERT-GV16 + Ad/GT-Bax.
Table 1
Susceptibility of parental, Bax-R and TRAIL-R DLD1 cells to adenoviral infection
Cells
CMV-GFP gTRAIL Positive cells (%) Mean intensity Positive cells (%) Mean intensity
Values are means ± s.d. for a quadruplicate assay, * P Ͻ 0.05, * * P Ͻ 0.01 compared with parental DLD1.
had levels of GFP expression equivalent to those of parental DLD1 cells treated with an MOI of 1000 vp/cell (Figure 2b ). Together, these results suggested that resistance to adenoviral infection may be responsible for resistance in DLD1/Bax-R cells.
Cell killing effects by dose escalation
To further investigate whether reduced transduction efficiency is sufficient to induce the resistance in DLD1/Bax-R cells, we infected DLD1/Bax-R cells with Ad/hTERT-GV16 + Ad/GT-Bax at a total MOI of 10 000 vp/cell. Cells infected with Ad/CMV-GFP at the same total MOIs were used as controls. Levels of apoptosis were then determined by FACS analysis and compared with the levels of apoptosis among parental DLD1 cells treated with Ad/hTERT-GV16 + Ad/GT-Bax at a total MOI of 1000 vp/cell (Figure 3a) . The level of apoptosis for DLD1/Bax-R cells treated with Ad/hTERT-GV16 + Ad/GT-Bax at a total MOI of 10 000 vp/cell was similar to that for parental DLD1 cells treated with the same vectors at a total MOI of 1000 vp/cell. DLD1/Bax-R cells treated with control vector at an MOI of 10 000 vp/cell showed only a background level of cell death similar to that of mock controls. This observation was further supported by cell viability assay with XTT ( Figure 3b) . A vector dose that resulted in transgene expression equivalent to that in parental DLD1 cells resulted in significant cell killing in DLD1/Bax-R cells, suggesting that reduced transduction efficiency may account for resistance in DLD1/Bax-R cells.
Susceptibility to adenoviral vectors expressing alternative proapoptotic genes
We then investigated whether DLD1/Bax-R or DLD1/TRAIL-R cells were susceptible to adenoviral vectors that expressed alternative proapoptotic genes without dose escalation. For this purpose, groups of parental DLD1, DLD1/Bax-R, and DLD1/TRAIL-R cells were treated with Ad/hTERT-GV16 + Ad/GT-Bax, Ad/hTERT-GV16 + Ad/GT-Bak, or Ad/gTRAIL at a total MOI of 1000 vp/cell. Apoptotic cell death was quantified by FACS assay. Parental DLD1 cells were susceptible to all the three treatments, whereas DLD1/Bax-R cells were resistant to adenoviral vectors expressing either the Bax or the Bak gene, but were susceptible to the adenoviral vector expressing the TRAIL gene. At 48 h after treatment with Ad/gTRAIL, about 36.4% of DLD1/Bax-R cells were apoptotic. In contrast, only background levels (Ͻ6.5%) of DLD1/Bax-R cells were apoptotic after treatment with adenoviral vectors expressing Gene Therapy either the Bax or the Bak gene. DLD1/TRAIL-R cells remained resistant to Ad/gTRAIL, but were susceptible to adenoviral vectors expressing either the Bax or the Bak gene. For DLD1/TRAIL-R cells, the level of apoptosis was 45.6% 48 h after treatment with Ad/hTERT-GV16 + Ad/GT-Bax and 54.3% at 48 h after treatment with Ad/hTERT-GV16 + Ad/GT-Bak (Figure 4a ). Cell viability assay with XTT showed similar results (Figure 4b) . Almost all parental DLD1 cells treated with Ad/hTERT-GV16 + Ad/GT-Bax, Ad/hTERT-GV16 + Ad/GT-Bak, or Ad/gTRAIL were apoptotic at 3 days after infection. In contrast, no significant difference was observed between groups of DLD1/Bax-R cells treated with Ad/hTERT-GV16 + Ad/GT-Bax, Ad/hTERT-GV16 + Ad/GT-Bak, or control vectors, but almost all DLD1/Bax-R cells treated with Ad/gTRAIL were killed. For DLD1/TRAIL-R cells, no difference in cell viability levels was observed between cells treated with Ad/gTRAIL and cells treated with control vector, but more than 80% of cells treated with Ad/hTERT-GV16 + Ad/GT-Bax or Ad/hTERT-GV16 + Ad/GT-Bak were killed. Together, these results suggested that DLD1/Bax-R and DLD1/TRAIL-R cells are susceptible to adenoviral vectors expressing proapoptotic genes involved in different apoptotic pathways or different models of cell killing, even without escalation of vector doses.
Molecular difference in parental DLD1, DLD1/Bax-R and DLD1/TRAIL-R cells
To investigate molecular differences among these three cells, we analyzed expression levels of several proteins that are known to be involved in Bax-or TRAIL-mediated apoptosis pathways, including Bcl2; Bcl-xL; Bcl-xS; DR4; DR5; DcR1; FLIP; Bax; Bak; XIAP and caspase-2, -7, -8, and -9. RNase protection assay and real-time PCR analysis were both used to determine mRNA levels. Western blot analysis was used to determine protein levels. Human GAPDH was used as an internal control for mRNAs. ␤-Actin was used as load control for Western blot analysis. In most cases, mRNA levels determined by RNase protection assay or real-time PCR assay correlated well with protein levels determined by Western blot analysis. However, there were some discrepancies. For example, the RNase protection assay showed comparable levels of DR4 expression between DLD1 and DLD1/TRAIL-R cells and a much lower level in DLD1/Bax-R cells. In contrast, Western blot analysis showed comparable DR4 levels between DLD1 and DLD1/Bax-R cells, but a slightly lower level in DLD1/TRAIL-R cells. In these cases, values that were consistent between the two methods of assay were considered true values. No dramatic differences were found for caspase-2, -7, -8, or -9; DR5; DcR1; Bcl-xS; Bcl-2; Bax; Bak; FLIP or XIAP among the parental DLD1, DLD1/Bax-R and DLD1/TRAIL-R cells (data not shown). However, Bcl-xL was up-regulated in DLD1/TRAIL-R cells with both RNA (real-time PCR) and protein levels about three times higher than those in either parental DLD1 or DLD1/Bax-R cells ( Figure 5 ).
Figure 4 Effects of adenoviral vectors expressing alternative proapoptotic genes. Parental DLD1, DLD1/Bax-R and DLD1/TRAIL-R cells were infected with different adenoviruses at a total MOI of 1000 vp/cell. Cells treated with PBS were used as a negative control. (a) Percentages of apoptotic (sub-G1) cells were determined by FACS 48 h after treatment. Left, cell lines; top, treatments; number within each panel, percentages of apoptotic cells. (b) Cell viability was determined 24, 48, and 72 h after treatment. Cells treated with PBS were used as a positive control, and their viability was set as 100%. Values are means ± s.d. for quadruplicate assays. In DLD1 cells, apoptosis levels after treatments with Ad/hTERT-GV16 + Ad/GT-Bax or Ad/hTERT-GV16 + Ad/GT-Bak or Ad/gTRAIL differed significantly from levels after treatments with PBS or Ad/CMV-GFP (P Ͻ 0.01). In DLD1/Bax-R cells, apoptosis levels after treatment with Ad/gTRAIL differed significantly from levels after treatment with PBS or Ad/CMV-GFP (P Ͻ 0.01), Ad/hTERT-GV16 + Ad/GT-Bax, and Ad/hTERT-GV16 + Ad/GT-Bak (P Ͻ 0.05). In DLD1/TRAIL-R cells, apoptosis levels after treatment with Ad/hTERT-GV16 + Ad/GT-Bax or Ad/hTERT-GV16 + Ad/GT-Bak differed significantly from levels after treatment with PBS, Ad/CMV-GFP, or
Bcl-xL overexpression does not protect DLD1 cells from TRAIL-, Bax-, or Bak-induced apoptosis
Because Bcl-xL was the only gene overexpressed as shown both by RNA levels and by protein levels in DLD1/TRAIL cells, we tested whether overexpression of the Bcl-xL gene is responsible for resistance in DLD1/TRAIL-R cells. DLD1 cells overexpressing Bcl-xL were then constructed by transfection with the plasmid pGT60-hBcl-xL and selected against hygromycin. Of seven hygromycin-resistant clones tested for Bcl-xL expression by Western blots, five overexpressed the BclxL gene at different levels (Figure 6a ). We then measured the level of apoptosis induced in each clone by treatment with adenoviral vectors expressing the Bax, Bak, or TRAIL gene. Regardless of the level of Bcl-xL expression, all five clones tested were susceptible to treatment with Ad/hTERT-GV16 + Ad/GT-Bax, Ad/hTERT-GV16 + Ad/GT-Bak, or Ad/gTRAIL. At 48 h after treatment, the percentage of apoptotic cells in sub-G1 phase ranged from 30.0% to 71.4% (Figure 6b ). These results suggested that Bcl-xL overexpression does not protect DLD1 cells from adenoviral vectors expressing the TRAIL, Bax, or Bak gene.
Discussion
Our results showed resistance developed in cancer gene therapy can be derived from two categories: 'reduced expression of therapeutic genes' and 'reduced susceptibility to a therapeutic gene'. In the first case, the resistance is caused by reduced vector entry or reduced expression of the therapeutic gene in the target cells. In the second case, the effects of the therapeutic gene are blocked even though the level of gene expression remains unchanged.
In adenovirus-mediated gene therapy, reduced gene transfer by adenoviral vectors could be due to changes in cell surface molecules that are responsible for adenovirus binding and internalization. We and others previously reported that low levels of coxsackievirus and adenovirus receptor (CAR); or integrins, such as ␣v␤3, ␣v␤5, or ␣5␤1, may reduce transduction efficiency of adenovirusmediated gene transfer. [23] [24] [25] [26] [27] However, resistance to adenoviral transduction can be overcome by using alternative vectors or by using adenoviral vectors with modified fibers or capsid proteins. For example, adenoviral vectors containing polylysine 26, 28 or an Arg-Gly-Asp (RGD) 29, 30 sequence have enhanced transduction efficiencies in cells refractory to conventional adenoviral vectors. In this study, DLD1/Bax-R cells showed reduced efficiency of transduction by adenoviral vector. Although the mechanisms remain to be characterized, it is likely that any changes in the cell surface molecules responsible for adenovirus binding and internalization can lead to reduced susceptibility to adenoviral infection. Because DLD1/Bax-R cells were susceptible to the treatment of Ad/hTERT-GV16 + Ad/GT-Bax at a dose that has levels of transgene expression similar to those found in parental DLD1 cells, the resistance to adenovirus-mediated Bax gene therapy in these cells is therefore largely caused by resistance to adenoviral infection. It is very likely that the parental tumors are heterogeneous in sensitivity to adenoviral infection. After majority of susceptible cells was killed via repeated infection, these resistant cells were selected and expanded. Interestingly, the Bax-R cells were susceptible to adenovirus-mediated TRAIL gene therapy, even without dose escalation. This finding may be due to bystander effect in the TRAIL gene therapy. We recently demonstrated that transduction with the TRAIL gene, but not the Bax gene resulted in bystander effects of susceptible neighboring cells. 5 Therefore, non-transduced DLD1/Bax-R cells may have been killed by bystander effect.
In the DLD1/TRAIL-R cells, the resistance to adenovirus-mediated TRAIL gene therapy is not caused by reduced susceptibility to adenoviral infection. Three main findings support this conclusion: first, transduction efficiency by adenovirus was not significantly changed in these cells. Second, the cells remain susceptible to adenovirus-mediated Bax gene therapy without dose escalation, even though the Bax gene therapy does not elicit the bystander effect. Finally, these cells are resistant to recombinant TRAIL protein. While parental DLD1 were effectively killed by recombinant TRAIL protein at a concentration of 5 ng/ml, DLD1/TRAIL-R were resistant to the TRAIL protein at a concentration of 500 ng/nl (data not shown). Therefore, resistance to adenovirus-mediated TRAIL gene therapy in these cells is mainly attributed to resistance to TRAIL-mediated apoptosis. Although the mechanisms have not yet been characterized, a survey of death receptors or death decoy receptors; caspases; FLIP; Bcl-2; Bcl-xL; Bcl-xS; Bax; Bak and XIAP by real-time PCR, RNase protection assays, or Western blot analysis showed that expression of Bcl-xL was dramatically increased in DLD1/TRAIL-R cells to levels three times those in parental DLD1 or DLD1/Bax-R cells. Reports on effects of Bcl-xL overexpression in susceptibility to recombinant TRAIL are controversial. One study showed that overexpression of Bcl-xL protected pancreatic adenocarcinoma cells against TRAIL-mediated apoptosis, 31 whereas another study showed that tumors overexpressing Bcl-2 or Bcl-xL remained sensitive to TRAIL-mediated apoptotis. 32 Our study showed that overexpression of Bcl-xL alone is not sufficient to render DLD1 cells resistant to TRAIL gene therapy. Moreover, since both Bcl-xLoverexpressed DLD1 cells and DLD1/TRAIL-R cells, which overexpresses Bcl-xL also, remain sensitive to adenovirus-mediated Bax or Bak gene therapy, suggesting the increase of the Bcl-xL is not sufficient to block the effects of Bax or Bak gene therapy. Because real-time PCR, RNase protection assay, and Western blot analysis cannot detect a mutation in the molecules tested, our results do not preclude the possibility of malfunction of these molecules tested in our study. It is possible that point mutations in death receptors, death decoy receptors, FLIP, or other molecules may be responsible for the resistance of DLD1/TRAIL-R cells.
The different mechanisms involved in DLD1/Bax-R and DLD1/TRAIL-R cells demonstrated that a variety of changes in cells can contribute to development of resistance to adenovirus-mediated proapoptotic gene therapy. Because cells resistant to adenovirus-mediated Bax gene therapy remained sensitive to adenovirus-mediated TRAIL gene therapy, and because cells resistant to adenovirus-mediated TRAIL gene therapy remained sensitive to adenovirus-mediated Bax gene therapy, it is likely that development of resistance can be prevented or overcome by using vectors that express genes in alternative apoptotic pathways or that have different mechanisms of inducing apoptosis.
Materials and methods
Cell lines and adenoviruses
Cells of the human colon cancer cell line DLD1 were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and antibiotics. DLD1 cells stably transfected with the human Bcl-xL gene were obtained by transfecting DLD1 cells with pGT60-hBcl-xL (InvivoGen, San Diego, CA, USA) using LipofectAMINE (Invitrogen, Carlsbad, CA, USA). Cells were then cultured in RPMI 1640 medium containing 500 g/ml hygromycin. Hygromycin-resistant single-cell clones overexpressing Bcl-xL were picked up and identified by Western blot analysis. The adenoviral vectors used, Ad/PGK-GV16, Ad/hTERT-GV16, Ad/GT-Bak, Ad/GT-Bax, Ad/GT-TRAIL, and Ad/CMV-GFP, were described previously. 2, 5 Ad/gTRAIL, a bicistronic adenoviral vector that expresses the GFP/TRAIL fusion protein 5 from the human telomerase reverse trancriptase (hTERT) promoter 2 via the GAL4 gene regulatory system, 33, 34 was recently constructed in our laboratory. Briefly, this vector contains two expression cassettes, one for GFP/TRAIL, whose gene is driven by a synthetic, minimal promoter composed of five sets of GAL4 binding sites and a TATAA sequence (GT promoter), the other for GAL4/VP16, a transactivator, whose gene is driven by the hTERT promoter. Both expression cassettes are inserted into the adenoviral E1 region, in a right-to-left sequence order direction, as GT-GFP/TRAIL-simian virus 40 polyadenylation signal-hTERT-GAL4/VP16-bovine growth hormone polyadenylation signal (detailed information on plasmid cloning and adenoviral vector construction is available upon request). The GAL4 gene regulatory components are included in the vector Ad/gTRAIL because our recent study showed that the yeast GAL4 gene regulatory system can augment transgene expression from a tumor-specific promoter without compromising promoter-specificity. 34 The expansion, purification, titration, and quality analysis of all the vectors used were performed at the vector core facility of our institution as described previously. 1, 2, 5 All the viral preparations were found to be free of the E1+ adenovirus by PCR assay and endotoxin by testing with a limulus amebocyte lysate endotoxin detection kit (BioWhittaker, Walkersville, MD, USA). The titer determined by the absorbency of the dissociated virus at A 260nm (one A 260nm unit = 10 12 vp/ml) was used in this study, whereas titers determined by plaque assay were used as additive information (information available upon request).
In vitro gene transfer DLD1 cells were infected with adenovirus at an MOI (measured in vp/cell) as described in the text. Ratios of particles:infectious units were usually between 30:1 and 100:1.
2,5 For example, an MOI of 1000 vp/cell is equival-ent to an MOI of 10-30 infectious units/cell. When two vectors were used in the experiments, cells were infected with the same total MOI as that used in single vectors, while the ratio of the two vectors was 1:1.
Cell viability assay
Cells were seeded on 96-well plates at densities of 1 × 10 4 cells/well 1 day before infection. After treatment with adenoviral vectors, the cell viability was measured by XTT assay using a cell proliferation kit ⌸ (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol as we have described previously.
1,2,5
Flow cytometry assays Flow cytometry analysis for GFP expression and apoptosis were performed in the Flow Cytometry Core Laboratory at our institution as we have previously described. 2, 5, 35 Western blot analysis Rabbit anti-human DR4, and mouse monoclonal antibodies against human Bax, Bak, XIAP, caspase-2, -7, and -8 were purchased from PharMingen (San Diego, CA, USA). Rabbit anti-human DR5 was obtained from Imegenex (San Diego, CA, USA). The rabbit antihuman/mouse FLIP was provided by R&D Systems (Minneapolis, MN, USA). The rabbit anti-human Bcl-2 and Bcl-xL/S were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For Western blot analysis, 80 g of total cellular proteins was separated by 10-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to Hybond enhanced chemiluminescence membranes (Amersham, Arlington Heights, IL, USA). Membranes were then blocked with blocking buffer containing 5% low-fat milk and 0.05% Tween-20 in PBS for 1 h or overnight at 4 o C, washed three times with PBS containing 0.05% Tween-20 (PBST), and then incubated with primary antibodies for at least 1 h at room temperature. After washing with PBST again, membranes were incubated with peroxidaseconjugated secondary antibodies and developed with a chemiluminescence detection kit (ECL kit, Amersham Phamarcia).
RNase protection assays
The total RNA was extracted using a total RNA isolation kit (PharMingen). RNase protection assay was performed according to the manufacturer's protocol (RiboQuant Multiprobe RNase Protection Assay System, PharMingen).
Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control for normalization of the mRNA amount.
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) analysis was performed in the ABI Prism 7700 Sequence Detection System according to the protocol of the manufacturer (Applied Biosystems, Foster City, CA, USA). Primers and probes for each gene tested were designed with built-in software in the 7700 System provided by Applied Biosystems and sysnthesized by Invitrogen (Frederick, MD, USA). Primers were placed in different exons of a gene to eliminate the effect from contaminated genomic DNA. For example, the forward primer for Bcl-xL was 5'-
